A complete SARS-CoV-2 testing workflow from RNA extraction through to qRT-PCR and rapid viral whole genome sequencing (WGS) to support testing laboratories.
Our high throughput service facility can perform up to 10,000 qRT-PCR COVID-19 tests per day ensuring test results are delivered quickly and efficiently.
If you are looking for a high throughput UK laboratory to process your SARS-CoV-2 (COVID-19) tests, we can help.
Viral RNA extraction service
Our viral RNA extraction service isolates viral RNA from nasopharyngeal swabs or other biofluids. We use a magnetic bead-based technology which is ideally suited to high through-put processing and enables us to carry out extractions at scale. The purification of high-quality RNA free from protein and other impurities is required for downstream qRT-PCR or rapid viral whole genome sequencing (WGS).
Find out more about our VirPath RNA extraction kit for COVID-19 testing laboratories.
SARS-CoV-2 multiplex qRT-PCR service.
Our SARS-CoV-2 qRT-PCR service uses the Nonacus VirPath SARS-CoV-2 Multiplex qRT-PCR Kit. This kit is CE-IVD marked and is one of the few COVID-19 qRT-PCR tests to pass the stringent accuracy and sensitivity requirements set for Fit to Fly, Test to Release and general COVID-19 testing.
- Detects all known variants
- CE-IVD marked
- Approved for Test to Release
Find out more about our VirPath Multiplex qRT-PCR kit for COVID-19 testing laboratories
SARS-CoV-2 whole genome sequencing
From 15 February 2021, all international arrivals in quarantine are required to take a test on or before day 2 of their quarantine period for variant surveillance. This will require whole genome sequencing of the SARS-CoV-2 genome in addition to the current qRT-PCR test.
We have over 6 years of experience in developing and manufacturing sequencing products and delivering sequencing services for diagnostic testing. In May 2020 we were funded by the UK Government (Innovate UK) to develop a novel rapid method for whole genome sequencing for viral surveillance which means we are well placed to offer customers this as a service.
SARS-CoV-2 WGS service
Our WGS service uses a robust and rapid method for whole genome sequencing of the SARS-CoV-2 virus that is ideally suited for the Test to Release programme and will deliver data that meet the required standards:
- All samples with cycle threshold (CT) values of <30 (defined as equivalent to ~10,000-1,000 viral genome copies/ml) will be sequenced.
- Coverage guarantees:
- All SARS-CoV-2 genomes will have a minimum sequencing coverage of 50% at >= 30x coverage.
- For samples with a CT <20, (defined as viral genome copy number equivalent of <1,000,000 viral genome copies per ml,) 95% of samples should have a reference genome coverage breadth of >97% at >=30x coverage.
- For CT above 20, defined as viral genome copy number equivalent of >1,000 per ml, 95% of samples should have a reference genome coverage breadth of >75% at >=30x coverage.
Nonacus was awarded an Innovate UK grant, to validate a novel, rapid method for sequencing respiratory viral genomes using nanopore sequencing.
SARS-CoV-2 Testing Products
The VirPath product range covers the complete testing workflow from RNA extraction to highly sensitive and accurate multiplex qRT-PCR.
High throughput service facility
Our high throughput service facility, based in Birmingham, UK, offers service support for the whole range of Nonacus panels
Saliva test could help meet Boris Johnson's 24-hour target - 6 June 2020
The Government is in talks with a British firm about rolling out a saliva test for coronavirus.
UK firm develops coronavirus spit test which could be done at home - 11 April 2020
A partnership between Nonacus Ltd and Chronomics has led to the development of a spit test for COVID-19.
We are very sorry but we are not authorized to provide SARS-CoV-2 test results on an individual basis. To get your results or any other information about your test please contact the diagnostic lab or testing centre from whom you purchased the test.